25 March 2015 - Deborah Wilkes
Archived
"An attractive opportunity" is how India's Sun Pharma describes the consumer healthcare business gained as part of its US$4.0 billion acquisition of Ranbaxy Laboratories from Japan's Daiichi Sankyo.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.